Total Payments
$1.4M
2024 Payments
$186,387
Companies
8
Transactions
1,442
Medicare Patients
873
Medicare Billing
$134,500
Payment Breakdown by Category
Other$987,677 (70.2%)
Consulting$239,324 (17.0%)
Travel$130,366 (9.3%)
Food & Beverage$26,833 (1.9%)
Research$21,875 (1.6%)
Education$92.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $987,677 | 356 | 70.2% |
| Consulting Fee | $239,324 | 70 | 17.0% |
| Travel and Lodging | $130,366 | 536 | 9.3% |
| Food and Beverage | $26,833 | 465 | 1.9% |
| Unspecified | $21,875 | 1 | 1.6% |
| Education | $92.99 | 14 | 0.0% |
Payments by Type
General
$1.4M
1,441 transactions
Research
$21,875
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | $541,248 | 566 | $0 (2024) |
| United Therapeutics Corporation | $414,502 | 453 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $364,659 | 351 | $0 (2024) |
| Merck Sharp & Dohme LLC | $53,748 | 39 | $0 (2024) |
| Actelion Pharmaceuticals, Ltd | $25,250 | 18 | $0 (2022) |
| Gilead Sciences, Inc. | $4,218 | 12 | $0 (2020) |
| Abbott Laboratories | $2,430 | 2 | $0 (2017) |
| Shockwave Medical, Inc | $112.98 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $186,387 | 159 | Actelion Pharmaceuticals US, Inc. ($83,278) |
| 2023 | $262,041 | 246 | Actelion Pharmaceuticals US, Inc. ($92,765) |
| 2022 | $204,803 | 175 | Actelion Pharmaceuticals US, Inc. ($83,841) |
| 2021 | $126,665 | 116 | United Therapeutics Corporation ($83,276) |
| 2020 | $88,599 | 62 | United Therapeutics Corporation ($40,572) |
| 2019 | $188,818 | 229 | Bayer HealthCare Pharmaceuticals Inc. ($107,726) |
| 2018 | $163,678 | 207 | Bayer HealthCare Pharmaceuticals Inc. ($123,377) |
| 2017 | $185,178 | 248 | Bayer HealthCare Pharmaceuticals Inc. ($115,899) |
All Payment Transactions
1,442 individual payment records from CMS Open Payments — Page 1 of 58
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,725.00 | General |
| Category: Cardiology | ||||||
| 12/18/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $24.93 | General |
| Category: Cardiology | ||||||
| 12/09/2024 | United Therapeutics Corporation | TYVASO (Drug), REMODULIN, ORENITRAM | Food and Beverage | In-kind items and services | $91.02 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 12/03/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $20.74 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/21/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Cardiology | ||||||
| 11/14/2024 | United Therapeutics Corporation | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,400.00 | General |
| 11/13/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $89.00 | General |
| Category: Cardiology | ||||||
| 11/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Adempas (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,147.00 | General |
| Category: Cardio-pulmonary | ||||||
| 11/07/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,725.00 | General |
| Category: Cardiology | ||||||
| 11/07/2024 | United Therapeutics Corporation | — | Food and Beverage | In-kind items and services | $124.99 | General |
| 11/07/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $104.14 | General |
| Category: Cardiology | ||||||
| 11/07/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $42.00 | General |
| Category: Cardiology | ||||||
| 11/07/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | Cash or cash equivalent | $18.92 | General |
| Category: Cardiology | ||||||
| 11/06/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,363.00 | General |
| Category: Cardiology | ||||||
| 11/04/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Food and Beverage | In-kind items and services | $79.74 | General |
| Category: Cardiology | ||||||
| 10/29/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Cardiology | ||||||
| 10/24/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Cardiology | ||||||
| 10/24/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | In-kind items and services | $378.51 | General |
| Category: Cardiology | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 10/23/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 10/16/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Travel and Lodging | In-kind items and services | $388.43 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Travel and Lodging | Cash or cash equivalent | $110.58 | General |
| Category: Cardiology | ||||||
| 10/08/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,725.00 | General |
| Category: Cardiology | ||||||
| 10/08/2024 | Actelion Pharmaceuticals US, Inc. | UPTRAVI (Drug), OPSUMIT | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,725.00 | General |
| Category: Cardiology | ||||||
| 10/08/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $22.29 | General |
| Category: Cardiology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| QUERI ACHD - AC-052433 USA | Actelion Pharmaceuticals US, Inc. | $21,875 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 204 | 315 | $94,140 | $34,261 |
| 2022 | 5 | 153 | 256 | $78,900 | $29,215 |
| 2021 | 12 | 286 | 434 | $115,930 | $42,805 |
| 2020 | 8 | 230 | 295 | $78,540 | $28,219 |
Total Patients
873
Total Services
1,300
Medicare Billing
$134,500
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 74 | 114 | $29,785 | $13,157 | 44.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 15 | 44 | $26,840 | $7,779 | 29.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 26 | 26 | $11,570 | $3,936 | 34.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 31 | $6,200 | $3,081 | 49.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 19 | 34 | $4,760 | $2,247 | 47.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 16 | 17 | $5,185 | $1,850 | 35.7% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2023 | 14 | 14 | $7,000 | $1,302 | 18.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 27 | 35 | $2,800 | $909.07 | 32.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 82 | 141 | $36,950 | $16,621 | 45.0% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 17 | 31 | $18,910 | $5,110 | 27.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 50 | $7,030 | $2,858 | 40.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $8,010 | $2,827 | 35.3% |
| 93451 | Insertion of tube in right heart chambers for measurement | Facility | 2022 | 16 | 16 | $8,000 | $1,798 | 22.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 74 | 98 | $26,060 | $12,109 | 46.5% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 21 | 48 | $29,280 | $9,027 | 30.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 32 | 102 | $14,310 | $6,244 | 43.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 21 | 21 | $9,345 | $3,346 | 35.8% |
| 93451 | Insertion of catheter for diagnostic evaluation of right heart structures | Facility | 2021 | 24 | 24 | $12,000 | $2,562 | 21.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 17 | $4,420 | $2,515 | 56.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 26 | 31 | $6,200 | $2,199 | 35.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 18 | $3,600 | $1,583 | 44.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 12 | 12 | $3,660 | $1,392 | 38.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 11 | 21 | $1,810 | $685.65 | 37.9% |
| 94621 | Test for exercise-induced heart and lung stress | Facility | 2021 | 12 | 12 | $2,670 | $682.19 | 25.6% |
| 94618 | Test for exercise-induced lung stress | Facility | 2021 | 12 | 12 | $955.00 | $230.52 | 24.1% |
About Dr. Paul Forfia, MD
Dr. Paul Forfia, MD is a Cardiovascular Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1245316058.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Paul Forfia, MD has received a total of $1.4M in payments from pharmaceutical and medical device companies, with $186,387 received in 2024. These payments were reported across 1,442 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($987,677).
As a Medicare-enrolled provider, Forfia has provided services to 873 Medicare beneficiaries, totaling 1,300 services with total Medicare billing of $134,500. Data is available for 4 years (2020–2023), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Cardiovascular Disease, Advanced Heart Failure and Transplant Cardiology
- Location Philadelphia, PA
- Active Since 10/27/2006
- Last Updated 04/16/2025
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1245316058
Products in Payments
- Adempas (Drug) $525,782
- UPTRAVI (Drug) $284,053
- ORENITRAM (Drug) $60,022
- REMODULIN (Drug) $46,123
- OPSUMIT (Drug) $32,524
- NONE (Drug) $29,033
- TYVASO (Drug) $20,267
- WINREVAIR (Biological) $14,669
- OPSUMIT MACITENTAN (Drug) $6,273
- CardioMEMS HF System (Device) $2,430
- Letairis (Drug) $1,793
- SHOCKWAVE IVL SYSTEM WITH THE SHOCKWAVE C2 CORONARY IVL CATHETER (Device) $112.98
- All-In-One (Device) $106.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Philadelphia
Quang Bui, Md, MD
Cardiovascular Disease — Payments: $1.0M
Cardiovascular Disease $1.0M
Anjali Vaidya, Md, MD
Cardiovascular Disease — Payments: $895,146
Cardiovascular Disease $895,146
Dean Karalis, Md, MD
Cardiovascular Disease — Payments: $760,521
Cardiovascular Disease $760,521
Ralph Verdino, Md, MD
Cardiovascular Disease — Payments: $683,076
Cardiovascular Disease $683,076
Francis Marchlinski, Md, MD
Cardiovascular Disease — Payments: $456,298
Cardiovascular Disease $456,298
Joshua Cooper, Md, MD
Cardiovascular Disease — Payments: $423,869
Cardiovascular Disease $423,869